|Daiichi Sankyo Pharmaceutical|
Daiichi Sankyo Pharmaceutical is a global pharmaceutical company founded in Japan. The company provides innovative products and services to around 20 countries in the world. It holds more than 100 years of scientific expertise, draws upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people suffering from a different health condition.
This well-known pharmaceutical company was founded on September 28, 2005, through the merger of Daiichi Pharmaceutical and Sankyo. Daiichi Sankyo Pharmaceutical delivers innovative products that enhance the lives of millions of people around the world.
The company has launched antihypertensive agent Olmesartan in 2002 and now available in more than 20 countries around the world; the antiplatelet agent prasugrel launched in 2009 for people with acute coronary syndrome undergoing percutaneous coronary intervention, and edoxaban, the first available factor Xa inhibitor in Japan, which launched in 2011 to help prevent venous thromboembolism.
It is a research-based pharmaceutical company that focuses on providing solutions to address the unmet medical needs of people around the world. It operates in a high-risk business sector. It continues to invest in Japanese, U.S., and European core markets, as well as emerging markets in developing and recently industrialized countries. Daiichi Sankyo Pharmaceutical’s diverse portfolio includes innovative and generic pharmaceuticals, vaccines, and over-the-counter medicines.